Literature DB >> 11263531

Gamma-rays enhance rAAV-mediated transgene expression and cytocidal effect of AAV-HSVtk/ganciclovir on cancer cells.

T Kanazawa1, M Urabe, H Mizukami, T Okada, A Kume, H Nishino, J Monahan, K Kitamura, K Ichimura, K Ozawa.   

Abstract

Adeno-associated virus (AAV) vector has several unique properties suited for gene therapy applications. However, relatively low efficiency of transgene expression, which is mainly due to a limited second-strand synthesis from the single-stranded AAV genome, can be a problem in some applications that require potent gene expression such as antitumor applications. Recently, gamma-ray irradiation has been reported to enhance the second-strand synthesis of the AAV genome, and consequently transgene expression. We demonstrate here that an AAV vector harboring the herpes simplex virus type-1 thymidine kinase (HSVtk) is able to kill cancer cells more efficiently when used in combination with gamma-ray irradiation. A human maxillary sinus cancer cell line, NKO-1, was efficiently killed in combination with HSVtk transduction and ganciclovir (GCV), as expected. More importantly, gamma-ray irradiation of practical dosages augmented the cytocidal effect of the HSVtk/GCV system. Southern analysis indicated that gamma-rays enhanced the double-strand synthesis of the rAAV genome in NKO-1 cells. These findings suggest that the combination of rAAVtk/GCV suicide gene therapy with radiotherapy has synergistic effects in the treatment of cancers and may lead to a reduction of the potential toxicity of both rAAVtk/GCV and gamma-ray irradiation.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11263531     DOI: 10.1038/sj.cgt.7700282

Source DB:  PubMed          Journal:  Cancer Gene Ther        ISSN: 0929-1903            Impact factor:   5.987


  9 in total

Review 1.  Adeno-associated virus vectors: potential applications for cancer gene therapy.

Authors:  Chengwen Li; Dawn E Bowles; Terry van Dyke; Richard Jude Samulski
Journal:  Cancer Gene Ther       Date:  2005-12       Impact factor: 5.987

2.  Chemotherapeutic agents enhance AAV2-mediated gene transfer into breast cancer cells promoting CD40 ligand-based immunotherapy.

Authors:  Bernd Koppold; Georg Sauer; Hildegard Buening; Michael Hallek; Rolf Kreienberg; Helmut Deissler; Christian Kurzeder
Journal:  J Cancer Res Clin Oncol       Date:  2006-06-23       Impact factor: 4.553

Review 3.  Hot topics in adeno-associated virus as a gene transfer vector.

Authors:  N Zhao; D P Liu; C C Liang
Journal:  Mol Biotechnol       Date:  2001-11       Impact factor: 2.695

4.  An experimental study on cervix cancer with combination of HSV-TK/GCV suicide gene therapy system and 60Co radiotherapy.

Authors:  Daozhen Chen; Qiusha Tang
Journal:  BMC Cancer       Date:  2010-11-06       Impact factor: 4.430

5.  Synergistic antitumor effect of AAV-mediated TRAIL expression combined with cisplatin on head and neck squamous cell carcinoma.

Authors:  Minghong Jiang; Zheng Liu; Yang Xiang; Hong Ma; Shilian Liu; Yanxin Liu; Dexian Zheng
Journal:  BMC Cancer       Date:  2011-02-03       Impact factor: 4.430

6.  Effect and mechanism of Mitomycin C combined with recombinant adeno-associated virus type II against glioma.

Authors:  Hong Ma; Yunjia Zhang; Hailong Wang; Chuanhui Han; Runhong Lei; Lei Zhang; Zuye Yang; Ling Rao; Hong Qing; Jim Xiang; Yulin Deng
Journal:  Int J Mol Sci       Date:  2013-12-19       Impact factor: 5.923

Review 7.  An overview of gene therapy in head and neck cancer.

Authors:  Amit Bali; Deepika Bali; Ashutosh Sharma
Journal:  Indian J Hum Genet       Date:  2013-07

8.  Enhanced efficacy of combination therapy with adeno‑associated virus-delivered pigment epithelium-derived factor and cisplatin in a mouse model of Lewis lung carcinoma.

Authors:  Sha-Sha He; Qin-Jie Wu; Chang Yang Gong; Shun-Tao Luo; Shuang Zhang; Meng Li; Lian Lu; Yu-Quan Wei; Li Yang
Journal:  Mol Med Rep       Date:  2014-04-04       Impact factor: 2.952

9.  An overview of targeted cancer therapy.

Authors:  Viswanadha Vijaya Padma
Journal:  Biomedicine (Taipei)       Date:  2015-11-28
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.